Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for <i>ALK-</i>Mutated NSCLC.

ABSTRACT:

Introduction

ALK tyrosine kinase inhibitors (ALK TKIs) are started at a standard dose regardless of patients' weight and body surface area (BSA). In this retrospective analysis, the authors explored whether body size variables were associated with toxicity and efficacy.

Methods

Retrospective data for ALK-positive patients at the Princess Margaret Cancer Centre were extracted from electronic health records. Associations between BSA/weight quartiles and dose reductions (DRs), temporary interruptions (TIs), and permanent discontinuation due to toxicity were evaluated using generalized linear mixed modeling. Survival analysis was conducted using Kaplan-Meier curves and log-rank tests.

Results

Among 142 patients with ALK-positive NSCLC treated between July 20

SUBMITTER: Munarriz BJ 

PROVIDER: S-EPMC12754393 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature